Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.
|Grade||Last Price||% Change||Price Change|
RARE closed down 0.18 percent on Wednesday, October 17, 2018, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to bounce off of its 200 day moving average, an important long-term support line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 1
|See historical RARE trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 17||200 DMA Support||Bullish||0.00%|
|Oct 17||NR7||Range Contraction||0.00%|
|Oct 17||Inside Day||Range Contraction||0.00%|
|Oct 17||Wide Bands||Range Expansion||0.00%|
|Oct 17||Oversold Stochastic||Weakness||0.00%|
|Oct 16||Slingshot Bearish||Bearish Swing Setup||-0.18%|
|Oct 16||Crossed Above 200 DMA||Bullish||-0.18%|
|Oct 16||Lower Bollinger Band Walk||Weakness||-0.18%|
|Oct 16||Wide Bands||Range Expansion||-0.18%|
|Oct 16||Oversold Stochastic||Weakness||-0.18%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more RARE news...
|52 Week High||90.98|
|52 Week Low||41.67|
|200-Day Moving Average||66.0097|
|50-Day Moving Average||78.9516|
|20-Day Moving Average||75.5955|
|10-Day Moving Average||68.998|
|Average True Range||3.9148|
|Chandelier Exit (Long, 3 ATRs )||79.2356|
|Chandelier Exit (Short, 3 ATRs )||72.3244|
|Upper Bollinger Band||92.1626|
|Lower Bollinger Band||59.0284|
|Percent B (%b)||0.21|
|MACD Signal Line||-3.4216|
|Market Cap||2.81 Billion|
|Num Shares||42.6 Million|
|Price-to-Earnings (P/E) Ratio||-9.80|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||69.13|
|Resistance 3 (R3)||68.88||67.61||68.62|
|Resistance 2 (R2)||67.61||66.82||67.73||68.44|
|Resistance 1 (R1)||66.82||66.33||67.22||67.07||68.27|
|Support 1 (S1)||64.76||64.76||65.16||65.01||63.81|
|Support 2 (S2)||63.49||64.27||63.61||63.64|
|Support 3 (S3)||62.70||63.49||63.47|
|Support 4 (S4)||62.95|